TrialBlood2009

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Hagop Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.